Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.
Department of Pneumology, Inselspital, Bern University Hospital, Bern, Switzerland.
J Allergy Clin Immunol. 2022 Aug;150(2):251-258. doi: 10.1016/j.jaci.2022.06.008.
With the development of targeted therapies for allergic diseases, the need for biomarkers supporting disease diagnosis and management has increased. Recent research has elucidated the pattern of cytokines and their distinct roles in the pathogenesis of allergic diseases. This means that cytokines should be considered as biomarkers. In this review article, we summarize published findings and critically discuss the use of cytokine measurements in association with disease diagnosis and management. Among the variety of suggested cytokines, thymus and activation-regulated chemokine (TARC) stands out and can indeed serve as a biomarker of atopic dermatitis. Both biologic characteristics and technical issues determine the reliability and limit the use of blood cytokines as biomarkers.
随着针对过敏性疾病的靶向治疗的发展,对支持疾病诊断和管理的生物标志物的需求不断增加。最近的研究阐明了细胞因子的模式及其在过敏性疾病发病机制中的独特作用。这意味着细胞因子应被视为生物标志物。在这篇综述文章中,我们总结了已发表的研究结果,并批判性地讨论了细胞因子测量在疾病诊断和管理中的应用。在各种建议的细胞因子中,胸腺激活调节趋化因子(TARC)引人注目,确实可以作为特应性皮炎的生物标志物。生物特性和技术问题共同决定了血液细胞因子作为生物标志物的可靠性和限制其应用。